Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer

2010139 citationsJournal Articlebronze Open Access

Authors

Diane Reidy‐Lagunes · Roswell Park Comprehensive Cancer Center

Efsevia Vakiani · Roswell Park Comprehensive Cancer Center

Marwan Fakih · Roswell Park Comprehensive Cancer Center

Muhammad Wasif Saif · Roswell Park Comprehensive Cancer Center

J. Randolph Hecht · Roswell Park Comprehensive Cancer Center

Noah Goodman-Davis · Roswell Park Comprehensive Cancer Center

Ellen Hollywood

Abstract

IMC-A12 alone or in combination with cetuximab was insufficient to warrant additional study in patients with colorectal cancer refractory to EGFR inhibitors.

Topics & Keywords

Colorectal Cancer Treatments and Studies Genetic factors in colorectal cancer Growth Hormone and Insulin-like Growth Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 28, Issue 27, pp. 4240-4246

DOI: 10.1200/jco.2010.30.4154

Field-Weighted Citation Impact: 10.29